My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: CTSU S1001

Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)


The purpose of this study is to give more intensive treatment to patients whose PET/CT shows that they have a greater chance of still having active lymphoma (PET/CT scan is positive after 3 cycles of therapy), and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma (PET/CT scan is negative after 3 cycles of therapy). Participants in this study have limited (or early stage) Diffuse Large B Cell non-Hodgkin Lymphoma (DLBCL). Limited (or early) Stage Diffuse Large B-cell non-Hodgkin Lymphoma is curable in many people, but some still can relapse (the cancer comes back), and some develop side-effects during or after treatment. A radiologic test called PET/CT scan is used in this study to determine treatment after three (3) cycles of a standard lymphoma chemotherapy called R-CHOP (the drugs are Rituximab, Cyclophosphamide, vincristine, doxorubicin, and prednisone). The agents used in this study are FDA approved for lymphoma treatment.

Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD
NHL (Non-Hodgkins Lymphoma)
Phase II


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list